Tasly Pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio
Tasly Pharmaceutical Group Co Ltd cash flow-to-debt ratio. Tasly Pharmaceutical Group Co Ltd (600535) has a Cash Flow-to-Debt Ratio of 0.20x as of December 2025, meaning its operating cash flow of CN¥552.13 Million could theoretically repay 0% of its total liabilities (CN¥2.79 Billion) in one year. Check Tasly Pharmaceutical Group Co Ltd (600535) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Tasly Pharmaceutical Group Co Ltd (2001–2025)
Cash flow-to-debt ratio of Tasly Pharmaceutical Group Co Ltd from 2001 to 2025. Historical debt coverage capacity for Tasly Pharmaceutical Group Co Ltd across 25 annual periods. Check cash flow reinvestment rate of Tasly Pharmaceutical Group Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Tasly Pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio by Year (2001–2025)
Tasly Pharmaceutical Group Co Ltd cash flow-to-debt ratio by year from 2001 to 2025. Year-by-year debt coverage analysis for Tasly Pharmaceutical Group Co Ltd. For the full cash flow conversion analysis, see 600535 cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.51x | CN¥1.42 Billion | CN¥2.79 Billion | ▼ -27.4% |
| 2024 | 0.70x | CN¥2.01 Billion | CN¥2.87 Billion | ▲ +9.9% |
| 2023 | 0.64x | CN¥2.58 Billion | CN¥4.02 Billion | ▲ +6.4% |
| 2022 | 0.60x | CN¥2.29 Billion | CN¥3.80 Billion | ▼ -30.7% |
| 2021 | 0.87x | CN¥2.80 Billion | CN¥3.23 Billion | ▲ +99.1% |
| 2020 | 0.44x | CN¥1.79 Billion | CN¥4.11 Billion | ▲ +215.2% |
| 2019 | 0.14x | CN¥1.68 Billion | CN¥12.15 Billion | ▲ +29.3% |
| 2018 | 0.11x | CN¥1.49 Billion | CN¥13.96 Billion | ▲ +263.3% |
| 2017 | -0.07x | CN¥-822.56 Million | CN¥12.56 Billion | ▼ -150.6% |
| 2016 | 0.13x | CN¥1.15 Billion | CN¥8.92 Billion | ▲ +193.2% |
| 2015 | 0.04x | CN¥340.00 Million | CN¥7.71 Billion | ▼ -43.8% |
| 2014 | 0.08x | CN¥616.76 Million | CN¥7.85 Billion | ▲ +37.7% |
| 2013 | 0.06x | CN¥346.17 Million | CN¥6.07 Billion | ▼ -54.7% |
| 2012 | 0.13x | CN¥413.31 Million | CN¥3.28 Billion | ▲ +166.6% |
| 2011 | 0.05x | CN¥135.14 Million | CN¥2.86 Billion | ▼ -75.7% |
| 2010 | 0.19x | CN¥395.05 Million | CN¥2.03 Billion | ▼ -9.8% |
| 2009 | 0.22x | CN¥400.39 Million | CN¥1.85 Billion | ▲ +12.5% |
| 2008 | 0.19x | CN¥260.21 Million | CN¥1.36 Billion | ▼ -3.0% |
| 2007 | 0.20x | CN¥221.55 Million | CN¥1.12 Billion | ▲ +116.8% |
| 2006 | 0.09x | CN¥140.56 Million | CN¥1.54 Billion | ▼ -49.5% |
| 2005 | 0.18x | CN¥214.90 Million | CN¥1.19 Billion | ▼ -26.5% |
| 2004 | 0.25x | CN¥203.27 Million | CN¥826.42 Million | ▲ +140.0% |
| 2003 | 0.10x | CN¥59.00 Million | CN¥575.74 Million | ▼ -87.4% |
| 2002 | 0.81x | CN¥206.22 Million | CN¥253.70 Million | ▲ +237.9% |
| 2001 | 0.24x | CN¥83.77 Million | CN¥348.19 Million | — |